What is the role of conservative primary surgical management of epithelial ovarian cancer: The United States experience and debate

International Journal of Gynecological Cancer

Volumn 15, Issue 6 SUPPL. 3, 2005, Pages 199-205

  Monk, Bradley J ^a   DiSaia, P J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Debulking; Fertility sparing; Ovarian cancer; Surgery

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONSERVATIVE TREATMENT; CYTOREDUCTIVE SURGERY; FEMALE FERTILITY; HUMAN; OMENTUM; OVARY; OVARY CANCER; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; UNITED STATES; UTERINE TUBE; UTERUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; INFERTILITY, FEMALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; REOPERATION; SURVIVAL ANALYSIS; UNITED STATES;

EID: 30744474998     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00429.x     Document Type: Review

References (28)

1. Epithelial ovarian cancer. In: DiSaia PJ, Creasman WT., eds. Clinical gynecologic oncology, 6th edn. 2002:289-350.
2. Schilder JM, Thompson AM, DePriest PD et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:1-7.
3. Berman ML. Future directions in the surgical management of ovarian cancer. Gynecol Oncol 2003;90:S33-9.
4. Eisenkop SM. Commenting on "future directions in the surgical management of ovarian cancer" by Berman. 90:S35-39. Gynecol Oncol 2004;94:235-6.
5. Spirtos NM, Pisani AL, Chen ND, Lim PL. Commenting on "future directions in the surgical management of ovarian cancer." Gynecol Oncol 2004;94:236-8.
6. Berman ML. In response to Dr. Eisenkop's letter concerning "future directions in the surgical management of ovarian cancer." Gynecol Oncol 2004;94:238-40.
7. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 1997;67:208-14.
8. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM. Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991;40:195-200.
9. Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med 2004;351:2544-6.
10. Chen L, Learman LA, Weinberg V, Powell CB. Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management. Int J Gynecol Cancer 2004;14:1055-62.
11. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72:93-9.
12. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-50.
13. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995;16:349-56.
14. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
15. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269-74.
16. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
17. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with sub-optimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9.
18. Rose PG, Nerenstone S, Brady MF et al. Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351: 2489-97.
19. Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cyto reduction in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:5605-12.
20. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
21. Berek JS. Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125. Gynecol Oncol 2000;77:225-6.
22. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:227-31.
23. Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 2004;95:377-83.
24. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11:166-72.
25. Morrow CP. An opinion in support of second-look surgery in ovarian cancer. Gynecol Oncol 2000;79:341-3.
26. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOGO 182-ICON5. Int J Gynecol Cancer 2003;13:735-40.
27. Greer BE, Bundy BN, Ozols RF et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group Study. Gynecol Oncol 2005 Jul 21; [epub ahead of print].
28. Berchuck A, Iversen ES, Lancaster JM et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004; 190:910-25.